drugset / Trial / NCT02457793
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or metastatic solid tumors for which standard therapies either do not exist or have proven ineffective or intolerable.
Timeline
- Start
- 2015-06-16
- Primary completion
- 2016-12-05
- Completion
- 2016-12-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobimetinib | Small molecule | 20 mg | Oral |
| Subject | Cobimetinib | Small molecule | 40 mg | Oral |
| Subject | Cobimetinib | Small molecule | 80 mg | Oral |
| Subject | Cobimetinib | Small molecule | 100 mg | Oral |
| Subject | RAVOXERTINIB | Small molecule | 200 mg | Oral |
| Subject | RAVOXERTINIB | Small molecule | 400 mg | Oral |